Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × Other neoplasm × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 48 Leukemia 12 Lymphoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Myelodysplastic Syndromes 9 Multiple Myeloma 9 Leukemia, Myeloid, Acute 9 Neoplasms, Plasma Cell 8 Myeloproliferative Disorders 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Mantle-Cell 8 Lymphoma, Large-Cell, Immunoblastic 8 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma, Follicular 8 Lymphoma, B-Cell, Marginal Zone 8 Burkitt Lymphoma 8 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7 Monoclonal Gammopathy of Undetermined Significance 7 Lymphoma, Large-Cell, Anaplastic 7 Leukemia, Biphenotypic, Acute 7 Immunoblastic Lymphadenopathy 7 Hodgkin Disease 7 Waldenstrom Macroglobulinemia 6 Uterine Cervical Dysplasia 6 Primary Myelofibrosis 6 Lymphoma, T-Cell, Cutaneous 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myeloid, Chronic-Phase 6 Leukemia, Myeloid, Accelerated Phase 6

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡